Byondis BV, a Netherlands-based, independent, privately held, clinical stage biopharmaceutical company, announced on Thursday that it has named Professor Timo K van den Berg, PhD as its new senior director, Immuno-Oncology Research and Development effective 1 September 2021.

Prof Van den Berg will operate out of the company's headquarters in Nijmegen. In the new role, ProfVan den Berg will help shape the company's IO pipeline, which includes the anti-SIRP alpha monoclonal antibody BYON4228.

Prof Van den Berg has over 30 years of experience in the IO field. He has served as head and principal investigator, Immunotherapy Laboratory, Department of Molecular Haematology at Sanquin Research, Amsterdam, the Netherlands and professor of Immunotherapy, Vrije Universiteit. He has 25 years of experience as research group leader and department head at Amsterdam University Medical Center and Sanquin Research. He is a member of many boards, including Amsterdam Infection and Immunity Institute and Cancer Center Amsterdam and his professional memberships include the Dutch Society of Immunology and the European Society for Clinical Investigation.